SCHEMBL334590

SCHEMBL334590

CCN(CCO)C(C)c1ccccc1OC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MC4R P32245 1/20 0.38
POLB P06746 1/20 0.38
HTT P42858 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
ALDH1A1 P00352 1/20 0.38
CYP1A2 P05177 2/20 0.37
AGTR1 P30556 1/20 0.37
LMNA P02545 1/20 0.37
CA1 P00915 3/20 0.36
CA2 P00918 3/20 0.36
CA12 O43570 1/20 0.36
CA4 P22748 1/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36
CA14 Q9ULX7 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36
ACHE P22303 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL334589 1.00 MC4R (0.38) MC4RPOLBHTTNPSR1L3MBTL1
SCHEMBL11886646 0.87 CA1 (0.44) MC4RPOLBHTTNPSR1L3MBTL1
SCHEMBL10245022 0.87 CA1 (0.44) MC4RPOLBHTTNPSR1L3MBTL1
SCHEMBL334999 0.84 TAAR1 (0.41) MC4RPOLBHTTNPSR1L3MBTL1
SCHEMBL12608137 0.84 ALDH1A1 (0.48) MC4RALDH1A1CA1CA2CA12
SCHEMBL1132754 0.84 TAAR1 (0.41) MC4RPOLBHTTNPSR1L3MBTL1
SCHEMBL10244221 0.83 ALDH1A1 (0.38) HTTL3MBTL1ALDH1A1LMNACA1
SCHEMBL12608991 0.83 MC4R (0.40) MC4RALDH1A1CA1CA2CA12
SCHEMBL10282712 0.82 SLC6A4 (0.43) POLBHTTNPSR1L3MBTL1ALDH1A1
SCHEMBL10244526 0.82 SLC6A4 (0.40) MC4RALDH1A1CYP1A2CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
EP-1985620-A1 10a-AZALIDE COMPOUND TAISHO PHARMACEUTICAL CO., LTD (JP) 2008-10-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 MC4R 3259/4885POLB 3348/4885HTT 868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.